ライフサイエンスコーパス: oral mucositis

1 toxicities (most often skin, respiratory, or oral mucositis).

2 d by the US Food and Drug Administration for oral mucositis.

3 with a history of oral GVHD and a history of oral mucositis.

4 tential therapy to prevent radiation induced oral mucositis.

5 lial cell growth in the tongues of mice with oral mucositis.

6 he expression of BAX in mice with IR-induced oral mucositis.

7 t no effective therapies to treat or prevent oral mucositis.

8 nd the incidence of severe radiation-induced oral mucositis.

9 ul association with severe radiation-induced oral mucositis.

10 uproleselan was associated with low rates of oral mucositis.

11 nt for cancer, does oral cryotherapy prevent oral mucositis?

12 up), lymphopenia (33 [28%] vs 20 [33%]), and oral mucositis (13 [11%] vs 11 [18%]).

13 ts [10.7%] vs 0 patients), and stomatitis or oral mucositis (13 patients [15.5%] vs 0 patients).

14 ls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (16 [3%] vs none), and fatigue (13 [3%] v

15 5 [12%]), fatigue (eight [6%] and 17 [14%]), oral mucositis (18 [14%] and two [2%]), and pain (ten [8

16 icant reductions in the incidence of grade 4 oral mucositis (20 percent vs. 62 percent, P<0.001), pat

17 6 of 73 [90%]), caries (35 of 73 [48%]), and oral mucositis (29 of 73 [40%]); 64 of 73 respondents (8

18 nic fever (10%) and during XPE, grade 3 or 4 oral mucositis (54%) and hypomagnesemia (39%).

19 recommended for prevention and treatment of oral mucositis, a painful condition that occurs in cance

20 romoter, were resistant to radiation-induced oral mucositis, a painful oral ulceration.

21 ifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiothe

22 Oral mucositis alters gene expression patterns, inhibits

23 d secondary endpoints were radiation-induced oral mucositis and neck dermatitis, respectively.

24 our data demonstrate that LiCl can mitigate oral mucositis and rescue taste alteration induced by ir

25 dification by caspase-3 following IR-induced oral mucositis and subsequently promotes the expression

26 Oral mucositis and taste dysfunction are frequently comp

27 evaluated the treatment efficacy of LiCl on oral mucositis and taste dysfunction in comparison with

28 ) describe the current preclinical models of oral mucositis and their contribution to the understandi

29 , both in the Q2W cohort (grade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash).

30 ew and swallow, increased risk of developing oral mucositis, and malnutrition.

31 regulation of mRNA turnover and apoptosis in oral mucositis, and our data suggest that blocking the c

32 reduced the incidence and duration of severe oral mucositis, as assessed by both clinicians and patie

33 tis was less severe in the Tac/Sir arm (peak Oral Mucositis Assessment Scale score 0.70 vs 0.96, P <

34 e RSpo1 to be a potent therapeutic agent for oral mucositis by enhancing basal layer epithelial regen

35 are in stage III clinical trials to prevent oral mucositis caused by radiation or chemo-therapy.

36 Oral mucositis causes substantial morbidity during head

37 Patients completed a daily questionnaire (Oral Mucositis Daily Questionnaire [OMDQ]) evaluating MT

38 me care group in relation to the symptoms of oral mucositis, diarrhea, constipation, nausea, pain, fa

39 of 40 patients), fatigue (eight [20%]), and oral mucositis (eight [20%]).

40 aminotransferase (eight [22%] vs none), and oral mucositis (five [14%] vs eight [24%]).

41 be considered at greater risk of developing oral mucositis following HCT.

42 developed as a topical treatment to mitigate oral mucositis following radiation.

43 aemia (11 [28%]), anorexia (nine [23%]), and oral mucositis (four [10%]).

44 rved that specific taxa were associated with oral mucositis grade and time to oral mucositis healing.

45 hile patients who did not develop ulcerative oral mucositis had a more resilient microbial ecosystem.

46 While oral mucositis has been well-described, its pathophysiol

47 Oral mucositis has emerged as a dose-limiting toxicity i

48 ciated with oral mucositis grade and time to oral mucositis healing.

49 ataemia in 16 (9%), lymphopenia in 25 (14%), oral mucositis in 19 (11%), and thrombocytopenia in 19 (

50 with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers;

51 yotherapy is effective for the prevention of oral mucositis in adults receiving fluorouracil-based ch

52 id cancers, and for the prevention of severe oral mucositis in adults receiving high-dose melphalan-b

53 in relation to the development of ulcerative oral mucositis in autologous SCT (autoSCT) recipients.

54 and therapeutic effects on radiation-induced oral mucositis in mice.

55 reating chemotherapy or radiotherapy-induced oral mucositis in several mouse models.

56 BMI was strongly related to the severity of oral mucositis in the head and neck cancer patients unde

57 MTX toxicity measures included the oral mucositis index (OMI), speed of engraftment (platel

58 trained examiner every 2 to 3 days using the Oral Mucositis Index (OMI).

59 Oral mucositis is a common toxicity of high-dose chemoth

60 Oral mucositis is a complication of intensive chemothera

61 Oral mucositis is a frequent and potentially severe comp

62 Oral mucositis is a nearly universal and often severe co

63 Oral mucositis is a significant problem in cancer patien

64 Oral mucositis is associated with significantly worse cl

65 igue (five [13%] vs six [15%] vs six [15%]), oral mucositis (none vs four [10%] vs one [3%]), and thr

66 urrence of mucositis, the median duration of oral mucositis of WHO grade 3 or 4 was 3 days (range, 0

67 The incidence of oral mucositis of World Health Organization (WHO) grade

68 Oral mucositis (OM) is a common and debilitating adverse

69 Oral mucositis (OM) is a complex acute cytotoxicity of a

70 Oral mucositis (OM) is a debilitating toxicity of chemor

71 Oral mucositis (OM) is a frequent complication of stem c

72 Oral mucositis (OM) is a serious and acute side effect i

73 Painful oral mucositis (OM) is a significant toxicity during rad

74 Oral mucositis (OM) is among the most common, painful, a

75 Oral mucositis (OM) remains a common, debilitating toxic

76 Oral mucositis (OM), a common debilitating toxicity asso

77 ention and treatment of chemotherapy-induced oral mucositis (OM).

78 had no significant effect on the severity of oral mucositis (OR: 0.3; 95% CI: 0.05, 1.67; P = 0.169).

79 (3) describe the proposed pathophysiology of oral mucositis pain and preclinical modeling of oral muc

80 d mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after admin

81 The primary end point was total oral mucositis pain reduction (defined by the area under

82 efinitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale,

83 l mucositis pain and preclinical modeling of oral mucositis pain.

84 For patients with oral mucositis, pain is the most distressing symptom, le

85 ntified new molecular mechanisms involved in oral mucositis pathogenesis, and our data suggest an alt

86 Oral mucositis refers to lesions of the oral mucosa obse

87 study, doxepin mouthwash was shown to reduce oral mucositis-related pain.

88 e of its importance in the clinical setting, oral mucositis remains under extensive laboratory and cl

89 Wnt/B-catenin signaling in radiation-induced oral mucositis (RIOM) and its pivotal role in the develo

90 his study was to evaluate factors predicting oral mucositis severity among 133 patients undergoing al

91 ) may serve as an alternative tool to assess oral mucositis severity in clinical trials.

92 ere is a large unmet medical need to prevent oral mucositis that can occur with radiation either alon

93 11 [8%]), lethargy (ten [7%] vs nine [7%]), oral mucositis (three [2%] vs 14 [10%]), vomiting (seven

94 hree [8%] each) in patients on pazopanib and oral mucositis (three [8%]) in those on placebo.

95 rade 3-4 treatment-related adverse event was oral mucositis (three [9%] of 33 participants), and seri

96 neutropenia via growth factors have elevated oral mucositis to a prominent toxicity of cancer therapy

97 ed and the presence or absence of ulcerative oral mucositis (UOM) was scored (WHO scale).

98 ere compared with clinicians' assessments of oral mucositis using the objective scales.

99 Oral mucositis was assessed by examination on days 1, 4,

100 Oral mucositis was evaluated daily for 28 days after tra

101 Oral mucositis was measured by a trained examiner every

102 Grade 2 to 3 oral mucositis was the predominant nonhematopoietic toxi

103 olution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test

104 activation, which is known to contribute to oral mucositis, we found activated transforming growth f

105 ) score during radiotherapy according to the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer

106 Oncologists frequently encounter oral mucositis, which can cause unplanned breaks in radi

107 d, with 3 DLTs across all schedules (grade 3 oral mucositis x 2; grade 4 sepsis x 1).